Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01736345 · ClinicalTrials.gov registry record
A Study of the Communication of Genetic Test Results By Telephone: A Multi-Center Study
A clinical trial, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- 289
- Enrollment target
NCT01736345: Completed study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT01736345 is a clinical trial that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 289 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01736345 has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- 289 participants
- Enrollment target
Study Summary
The overall goal of the proposed research is to evaluate psychosocial and behavioral outcomes (i.e.risks and benefits) of an innovative and efficient delivery model for genetic testing, telephone communication, as an alternative to in-person communication of genetic testing results to inform guidelines regarding the delivery of genetic information in clinical medicine.
Interventions
- GENETIC Genetic Providers
- OTHER Visual Aids
- OTHER Post-Disclosure Asessments
- OTHER In-person Clinical Follow-Up
- OTHER 6 Month and 12 Month Assessments
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 289 participants |
| Start Date | 2012-12-03 |
| Est. Completion | 2015-11 |
What the finished NCT01736345 record still lists
NCT01736345 is an observational study that tracks outcomes without assigning an intervention. The registered 289 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 5 interventions - of which Genetic Providers is the first listed.
NCT01736345 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01736345 about?
NCT01736345 is a clinical study titled "A Study of the Communication of Genetic Test Results By Telephone: A Multi-Center Study". The overall goal of the proposed research is to evaluate psychosocial and behavioral outcomes (i.e.risks and benefits) of an innovative and efficient delivery model for genetic testing, telephone communication, as an alternative to in-person communication of genetic testing results to inform guideli...
What is the current status of trial NCT01736345?
This trial is currently completed. The enrollment target is 289 participants. The study started on 2012-12-03. Estimated completion is 2015-11.
What interventions are being tested in trial NCT01736345?
The interventions under investigation include: Genetic Providers (GENETIC), Visual Aids (OTHER), Post-Disclosure Asessments (OTHER), In-person Clinical Follow-Up (OTHER), 6 Month and 12 Month Assessments (OTHER).
Who is sponsoring clinical trial NCT01736345?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06465199 · 289 participants · Phase 1
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
- NCT00775476 · 290 participants · Phase 2
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
- NCT01874197 · 290 participants · NA
Branched Thoracic Endovascular Grafts for the Treatment of Thoraco-abdominal Aortic
- NCT04331353 · 290 participants · NA
The Allergen Reduction and Child Health Study (ARCHS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI